SecBot SecBot
424B5 ·Filed Nov 12, 2026

PEPG

PepGen Inc.
BEARISH
Impact 6/10
Horizonimmediate Processed4d 10h ago SEC0001193125-26-458571
Notable filing: 424B5
Actionable Insight ▼ Bearish

The offering was priced at a premium to the prior close ($5.00 vs $4.61), suggesting strong underwriter demand, but the 36% dilution is substantial for a company with a $319M pre-offering market cap (at $4.61). Monitor the stock's trading volume and price action around the November 13 closing date. The company's cash runway now extends into 2028, but the unresolved FDA partial clinical hold on FREEDOM2 remains a key risk. Watch for any insider selling after the 60-day lock-up expires.

DirectionBearish
Confidencehigh
Horizonimmediate

PGN-EDODM1

▲ Bullish Named in this 424B5
Impact
Phase
Phase 2
Time to market
At least 2-3 years away, assuming positive Phase 2 data in November 2026, an end-of-Phase 2 meeting with regulators in 1H 2027, a subsequent Phase 3 program, and eventual NDA filing.
Next catalyst
None dated

What to watchWatch for the 10 mg/kg data readout from the FREEDOM2-DM1 study expected in November 2026, positive splicing-correction data could drive a significant re-rate given the stock's ~$3.11 price vs. the $10.19 mean analyst target. However, the unresolved FDA partial clinical hold and the active $100M ATM facility are overhangs that could cap upside or accelerate dilution.

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$4.36
T+0 close · Nov 12, 2026 · via day close
Latest settled
−3.90%
T+1 · $4.19
Vs SPY
−1.99%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $4.36entry
  2. T+1 · 20h ago −3.90%α −1.99% · $4.19
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

PepGen is offering 25,000,000 shares of common stock at $5.00 per share in a priced underwritten equity offering, raising gross proceeds of $125 million ($116.9 million net). The offering represents a 36.1% dilution to the 69,261,055 shares outstanding as of September 30, 2026. Proceeds will fund clinical development of PGN-EDODM1 and general corporate purposes. The offering follows positive Phase 2 FREEDOM2-DM1 results reported on November 10, 2026, and comes two days after that earnings release, signaling an urgent capital need despite the positive data.

Key Financial Metrics

Offering Size
$125.0M
Dilution
36.1%
Lock-up
60 days
Underwriters
Leerink Partners LLC, Stifel, Nicolaus & Company, Incorporated +3

Key Facts

  • Offering of 25,000,000 shares of common stock at $5.00 per share
  • Gross proceeds of $125,000,000; net proceeds of approximately $116,900,000
  • Underwriters have a 30-day option to purchase up to an additional 3,750,000 shares
  • Shares outstanding after offering: 94,261,055 (or 98,011,055 if option exercised in full)
  • Dilution of 36.1% based on 69,261,055 shares outstanding as of September 30, 2026
  • Public offering price of $5.00 vs. closing price of $4.61 on November 10, 2026 (a 8.5% premium)
  • Immediate dilution of $2.67 per share to new investors based on net tangible book value
  • Lock-up agreements for 60 days for company, directors, and executive officers
  • Net proceeds to fund clinical development of PGN-EDODM1 and for working capital
  • Company had cash of $104.8 million as of September 30, 2026, sufficient into 2028

Financial Impact

Gross proceeds of $125 million; net proceeds of approximately $116.9 million; 36.1% dilution to existing shareholders

dilutioncashshare count

Risk Factors

  • 36.1% dilution from the offering may pressure the stock price
  • Unresolved FDA partial clinical hold on the FREEDOM2 study in the U.S.
  • Company expects additional capital will be needed beyond this offering to complete development
  • Remaining $98.5 million ATM capacity with Stifel creates further overhang
  • 60-day lock-up expiration could lead to insider selling

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001193125-26-458571
Document: 0001193125-26-458571-index-headers.html0001193125-26-458571
Document: 0001193125-26-458571-index.html0001193125-26-458571
Document: 0001193125-26-458571.txt0001193125-26-458571

Track record

12 reports on PEPG

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +31.95% at T+20 after the Aug 6, 2026 report. 5 of 6 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Bearish 6/10 Entry $4.36 to $4.19 Now $4.19 +3.90% ▲ +3.90% +1.99% vs SPY
  2. Nov 12, 20264d ago 424B5 Bearish 6/10 Viewing Entry $4.36 to $4.19 Now $4.19 +3.90% ▲ +3.90% +1.99% vs SPY
  3. Nov 10, 20266d ago 424B5 Bearish 6/10 Entry $5.26 to $5.04 Now $4.19 +20.34% ▲ +4.18% +3.83% vs SPY
  4. Nov 10, 20266d ago 8-K Bullish 7/10 Entry $4.61 to $5.26 Now $4.19 −9.11% ▲ +14.10% +12.78% vs SPY
  5. Aug 6, 202614w ago 8-K Bullish 7/10 Entry $2.41 to $2.85 Now $4.19 +73.86% ▲ +18.26% +17.65% vs SPY
  6. Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $1.51 to $1.47 Now $4.19 +177.48% ▼ −2.65% −3.19% vs SPY
  7. Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $1.51 to $1.47 Now $4.19 +177.48% ▼ −2.65% −3.19% vs SPY
  8. May 22, 202625w ago EFFECT Bearish 7/10 Entry $1.51 to $1.53 Now $4.19 −177.48% ▼ −1.32% −0.74% vs SPY
  9. May 19, 202625w ago S-3 Bearish 7/10 Entry $1.38 to $1.44 Now $4.19 −203.62% ▼ −4.35% −3.31% vs SPY
  10. May 12, 202626w ago 8-K Neutral 5/10 Entry $1.78 to $1.78 Now $4.19 +135.39% · 0.00% +0.00% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026